CAPRICOR THERAPEUTICS, INC. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
Capricor's lead candidate Deramiocel (CAP-1002) for DMD showed statistically significant slowing of upper limb disease progression (p=0.029) in the HOPE-3 Phase 3 trial, published in The Lancet. The BLA remains under active FDA review following a July 29 Advisory Committee vote (3 in favor, 9 against on cardiomyopathy indication); the company reported cash of $237.9M as of June 30, 2026, down from $318.1M at year-end 2025, with H1 2026 operating expenses of $79.7M and net loss of $74.7M.
Why this rating
Primary endpoint met is positive; but Advisory Committee rejection on requested indication and FDA inspection (Form 483) create material regulatory uncertainty. Cash burn ($80M in 6 months) and $80.2M liability increase are concerning relative to $399M market cap. Outcome hinges entirely on FDA's next move.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.